ImmunityBio, Inc.

NASDAQ:IBRX

Biotechnology

Healthcare
$6.57 +2.58%

+$0.18 today

Market cap
$6.99B
Beta
0.10
P/E (TTM)
-8.6
EPS (TTM)
-$0.83
52W Low $1.95High $12.43

Volume 11.10M

Average 16.40M

Income Statement

Follow revenue through to earnings.

Revenue

$113.29M

FY 2025 · Annual

+668.3% YoY

Operating Income

-$256.03M

FY 2025 · Annual

Net Income

-$351.40M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue934K240K622K14.75M113.29M
Cost of Revenue0000753K
Gross Profit934K240K622K14.75M112.54M
Gross Margin100.0%100.0%100.0%100.0%99.3%
Research & Development195.96M248.15M232.37M190.14M207.88M
Selling, General & Admin135.26M102.71M129.62M168.78M147.18M
Operating Expenses331.21M351.54M362.87M358.93M368.56M
Depreciation & Amortization14.24M18.26M18.51M17.55M15.53M
EBITDA(320.75M)(351.88M)(478.66M)(264.43M)(223.56M)
EBITDA Margin-34341.8%-146617.1%-76955.5%-1793.4%-197.3%
Operating Income(330.28M)(351.3M)(362.25M)(344.18M)(256.03M)
Operating Margin-35361.9%-146374.2%-58239.5%-2334.2%-226.0%
Interest Income836K2.71M863K2.4M6.7M
Interest Expense14.85M47.15M86.72M131.66M112.53M
Other Income / Expenses(19.56M)(65.99M)(221.64M)(69.46M)(95.58M)
Income Before Tax(349.84M)(417.29M)(583.89M)(413.65M)(351.61M)
Pre-Tax Margin-37456.0%-173869.2%-93873.3%-2805.3%-310.4%
Income Tax Expense9K34K(40K)0(135K)
Net Income(346.79M)(416.57M)(583.2M)(413.56M)(351.4M)
Net Margin-37129.6%-173569.6%-93761.4%-2804.8%-310.2%
EPS (Basic)(0.89)(1.04)(1.15)(0.59)(0.38)
EPS (Diluted)(0.89)(1.04)(1.15)(0.62)(0.38)
Weighted Avg Shares389.23M399.9M508.64M697.31M919.86M
Weighted Avg Shares (Diluted)389.23M399.9M508.64M700.44M919.86M

IBRX Earnings Waterfall · TTM

NASDAQ:IBRX · Revenue to Net Income

Key Ratios

EPS$-1.08
Gross Margin96.3%
Net Margin-605.2%
P/E Ratio-8.7
P/S Ratio153.4

Analysis

$182.6M of revenue converted into -$1.1B of net income for the selected period. Gross margin is 96.3% and net margin is -605.2%, showing how much revenue survives after costs and taxes. EPS is $-1.08, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
10-QQuarterly reportNov 9, 2026
8-KCurrent reportNov 9, 2026
8-KCurrent reportNov 9, 2026
8-KCurrent reportOct 14, 2026
4Statement of changes in beneficial ownershipOct 6, 2026

How much revenue does IBRX generate?

ImmunityBio, Inc. (IBRX) reported $113.29M of revenue in fiscal 2025.

Is IBRX profitable?

ImmunityBio, Inc. (IBRX) reported -$351.40M of net income, with a net margin of -310.2%.